FRANKFURT (Reuters) -Bayer stated on Wednesday its Nubeqa drug was proven to sluggish the development of a sure sort of prostate most cancers in a late-stage trial, underpinning development prospects for one of many German drugmaker’s key pharmaceutical merchandise.
Bayer is growing Nubeqa, also called darolutamide, collectively with Finland’s Orion. The drug is already authorized in different prostate most cancers remedy settings.
Bayer stated in a press release that Nubeqa, when mixed with androgen deprivation remedy, considerably extended progression-free survival in comparison with androgen deprivation remedy alone in a part III path.
Trial individuals suffered from a kind of metastatic prostate most cancers that responds to hormone remedy.
Particulars of the trial could be offered at an as but undisclosed medical convention, Bayer stated, including that it plans to hunt regulatory approval for wider use of the drug.
(Reporting by Ludwig Burger, Enhancing by Rachel Extra)
By Ludwig Burger
